These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37424799)

  • 41. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis.
    Lian W; Zheng J; Chen D
    Transl Cancer Res; 2020 Oct; 9(10):5969-5978. PubMed ID: 35117209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
    Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
    Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
    [No Abstract]   [Full Text] [Related]  

  • 45. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K; Parise C; Caggiano V
    BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
    Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
    Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
    Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
    Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
    Park S; Lee SK; Paik HJ; Ryu JM; Kim I; Bae SY; Yu J; Kim SW; Lee JE; Nam SJ
    Medicine (Baltimore); 2017 Jun; 96(22):e6777. PubMed ID: 28562530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
    Nguy S; Wu SP; Oh C; Gerber NK
    Breast Cancer Res Treat; 2021 Jun; 187(3):815-830. PubMed ID: 33590386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast Cancer in Elderly Caucasian Women-An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall Survival.
    Orucevic A; Curzon M; Curzon C; Heidel RE; McLoughlin JM; Panella T; Bell J
    Cancers (Basel); 2015 Jul; 7(3):1472-83. PubMed ID: 26264027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.
    Chun YS; Mizuno T; Cloyd JM; Ha MJ; Omichi K; Tzeng CD; Aloia TA; Ueno NT; Kuerer HM; Barcenas CH; Vauthey JN
    Eur J Surg Oncol; 2020 Sep; 46(9):1588-1595. PubMed ID: 32253074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
    Parise CA; Caggiano V
    Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.